- Home
- ANY vs LITS Comparison
ANY vs LITS Comparison
Compare ANY & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | LITS |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 25.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANY | LITS |
|---|---|---|
| Price | $2.73 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 6.0M | 520.2K |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | N/A |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.69 |
| 52 Week High | $6.20 | $3.03 |
Technical Indicators
Market Signals| Indicator | ANY | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 47.68 |
| Support Level | $1.33 | $0.69 |
| Resistance Level | $4.29 | $1.23 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 9.76 | 63.62 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.